Article
Oncology
Rachel Michaelson-Cohen, Shira Gabizon-Peretz, Shunit Armon, Naama Srebnik-Moshe, Pnina Mor, Ariela Tomer, Ephrat Levy-Lahad, Shani Paluch-Shimon
Summary: This study found that short-term post-RRSO HRT use was associated with a threefold risk of BC in BRCA1/BRCA2 carriers older than 45 years. These results suggest that risk may be related to time of exposure to HRT around the natural age of menopause, even among carriers of BRCA1/2.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Trine Koch, Jeanette Therming Jorgensen, Jane Christensen, Christian Dehlendorff, Laerke Priskorn, Mette K. Simonsen, Anne Katrine Duun-Henriksen, Zorana J. Andersen, Anders Juul, Elvira V. Brauner, Martha Hickey
Summary: The study found that unilateral and bilateral oophorectomy is associated with a reduced breast cancer rate in women from the general population, and this association is not modified by use of HRT, hysterectomy, BMI, or shift work.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
India Hickey, Swati Jha, Lynda Wyld
Summary: This study explored the psychosexual impacts of risk-reducing bilateral salpingo-oophorectomy, with results indicating that women undergoing the surgery often feel unprepared for the psychological and sexual side effects. RRBSO was found to commonly cause distress and problems for women and their partners.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Siddhartha Yadav, Nicholas J. Boddicker, Jie Na, Eric C. Polley, Chunling Hu, Steven N. Hart, Rohan D. Gnanaolivu, Nicole Larson, Susan Holtegaard, Huaizhi Huang, Carolyn A. Dunn, Lauren R. Teras, Alpa V. Patel, James V. Lacey, Susan L. Neuhausen, Elena Martinez, Christopher Haiman, Fei Chen, Kathryn J. Ruddy, Janet E. Olson, Esther M. John, Allison W. Kurian, Dale P. Sandler, Katie M. O'Brien, Jack A. Taylor, Clarice R. Weinberg, Hoda Anton-Culver, Argyrios Ziogas, Gary Zirpoli, David E. Goldgar, Julie R. Palmer, Susan M. Domchek, Jeffrey N. Weitzel, Katherine L. Nathanson, Peter Kraft, Fergus J. Couch
Summary: The purpose of this study was to estimate the risk of contralateral breast cancer (CBC) among women with germline pathogenic variants (PVs) in ATM, BRCA1, BRCA2, CHEK2, and PALB2. The results showed that BRCA1, BRCA2, and CHEK2 PV carriers with breast cancer had significantly higher risks of CBC, while only PALB2 PV carriers with ER-negative breast cancer had elevated risks. However, ATM PV carriers did not have significantly increased CBC risks. The study suggests that women diagnosed with breast cancer and known to carry germline PVs in certain genes may benefit from enhanced surveillance and risk reduction strategies.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Joanne Kotsopoulos, Jan Lubinski, Jacek Gronwald, Janusz Menkiszak, Jeanna McCuaig, Kelly Metcalfe, William D. Foulkes, Susan L. Neuhausen, Sophie Sun, Beth Y. Karlan, Andrea Eisen, Nadine Tung, Olufunmilayo Olopade, Fergus J. Couch, Tomasz Huzarski, Leigha Senter, Louise Bordeleau, Christian F. Singer, Charis Eng, Robert Fruscio, Tuya Pal, Ping Sun, Steven A. Narod
Summary: The study suggests that bilateral oophorectomy is unlikely to determine the risk of breast cancer in BRCA1 mutation carriers, but it should be offered at age 35 to reduce the risk of ovarian and fallopian tube cancer.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Renata Faermann, Eitan Friedman, Orit Kaidar-Person, Malka Brodsky, Osnat Halshtok Neiman, Anat Shalmon, Michael Gotlieb, Yael Yagil, David Samocha, Dana Madorsky Feldman, Jonathan Weidenfeld, Miri Sklair-Levy
Summary: This study summarizes the experience at the largest high-risk clinic in Israel regarding breast cancer screening for pregnant and breastfeeding women who are carriers of the BRCA gene. The results show a pregnancy-associated breast cancer detection rate of 2.05%, with over half of the cases detected through screening. Therefore, despite the changes in breast tissue during pregnancy and breastfeeding, screening plays an important role in early detection, and ultrasound should be considered as a screening tool for high-risk patients.
ACADEMIC RADIOLOGY
(2023)
Article
Oncology
Emma J. Crosbie, Nicola Flaum, Elaine F. Harkness, Richard D. Clayton, Cathrine Holland, Pierre Martin-Hirsch, Nick Wood, Patrick Keating, Emma R. Woodward, Fiona Lalloo, Paul Donnai, Richard J. Edmondson, D. Gareth Evans
Summary: RRBSO is highly effective in reducing the risk of high-grade serous ovarian cancer and primary peritoneal cancer in individuals with BRCA1/2 pathogenic variants, although it does not completely eliminate the risk. Detailed screening and treatment in specialist centers may have an impact on the risk reduction effect post-surgery.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Review
Oncology
Yizi Wang, Zixuan Song, Shitai Zhang, Xiaoying Wang, Peiwen Li
Summary: RRSO is an effective method to reduce BC risk among women with BRCA1/2 mutation, especially in younger women. The immediate 5 years after surgery is the most beneficial time period for RRSO.
Article
Multidisciplinary Sciences
Juliette Coignard, Michael Lush, Jonathan Beesley, Tracy A. O'Mara, Joe Dennis, Jonathan P. Tyrer, Daniel R. Barnes, Lesley McGuffog, Goska Leslie, Manjeet K. Bolla, Muriel A. Adank, Simona Agata, Thomas Ahearn, Kristiina Aittomaeki, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Norbert Arnold, Kristan J. Aronson, Banu K. Arun, Annelie Augustinsson, Jacopo Azzollini, Daniel Barrowdale, Caroline Baynes, Heko Becher, Marina Bermisheva, Leslie Bernstein, Katarzyna Bialkowska, Carl Blomqvist, Stig E. Bojesen, Bernardo Bonanni, Ake Borg, Hiltrud Brauch, Hermann Brenner, Barbara Burwinkel, Saundra S. Buys, Trinidad Caldes, Maria A. Caligo, Daniele Campa, Brian D. Carter, Jose E. Castelao, Jenny Chang-Claude, Stephen J. Chanock, Wendy K. Chung, Kathleen B. M. Claes, Christine L. Clarke, J. Margriet Collee, Don M. Conroy, Kamila Czene, Mary B. Daly, Peter Devilee, Orland Diez, Yuan Chun Ding, Susan M. Domchek, Thilo Dork, Isabel dos-Santos-Silva, Alison M. Dunning, Miriam Dwek, Diana M. Eccles, A. Heather Eliassen, Christoph Engel, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Henrik Flyger, Florentia Fostira, Eitan Friedman, Lin Fritschi, Debra Frost, Manuela Gago-Dominguez, Susan M. Gapstur, Judy Garber, Vanesa Garcia-Barberan, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Mia M. Gaudet, Simon A. Gayther, Andrea Gehrig, Vassilios Georgoulias, Graham G. Giles, Andrew K. Godwin, Mark S. Goldberg, David E. Goldgar, Anna Gonzalez-Neira, Mark H. Greene, Pascal Guenel, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Patricia A. Harrington, Steven N. Hart, Wei He, Frans B. L. Hogervorst, Antoinette Hollestelle, John L. Hopper, Darling J. Horcasitas, Peter J. Hulick, David J. Hunter, Evgeny N. Imyanitov, Agnes Jager, Anna Jakubowska, Paul A. James, Uffe Birk Jensen, Esther M. John, Michael E. Jones, Rudolf Kaaks, Pooja Middha Kapoor, Beth Y. Karlan, Renske Keeman, Elza Khusnutdinova, Johanna I. Kiiski, Yon-Dschun Ko, Veli-Matti Kosma, Peter Kraft, Allison W. Kurian, Yael Laitman, Diether Lambrechts, Loic Le Marchand, Jenny Lester, Fabienne Lesueur, Tricia Lindstrom, Adria Lopez-Fernandez, Jennifer T. Loud, Craig Luccarini, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, John W. M. Martens, Noura Mebirouk, Alfons Meindl, Austin Miller, Roger L. Milne, Marco Montagna, Katherine L. Nathanson, Susan L. Neuhausen, Heli Nevanlinna, Finn C. Nielsen, Katie M. O'Brien, Olufunmilayo I. Olopade, Janet E. Olson, Hakan Olsson, Ana Osorio, Laura Ottini, Tjoung-Won Park-Simon, Michael T. Parsons, Inge Sokilde Pedersen, Beth Peshkin, Paolo Peterlongo, Julian Peto, Paul D. P. Pharoah, Kelly-Anne Phillips, Eric C. Polley, Bruce Poppe, Nadege Presneau, Miquel Angel Pujana, Kevin Punie, Paolo Radice, Johanna Rantala, Muhammad U. Rashid, Gad Rennert, Hedy S. Rennert, Mark Robson, Atocha Romero, Maria Rossing, Emmanouil Saloustros, Dale P. Sandler, Regina Santella, Maren T. Scheuner, Marjanka K. Schmidt, Gunnar Schmidt, Christopher Scott, Priyanka Sharma, Penny Soucy, Melissa C. Southey, John J. Spinelli, Zoe Steinsnyder, Jennifer Stone, Dominique Stoppa-Lyonnet, Anthony Swerdlow, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Mary Beth Terry, Alex Teule, Darcy L. Thull, Marc Tischkowitz, Amanda E. Toland, Diana Torres, Alison H. Trainer, Therese Truong, Nadine Tung, Celine M. Vachon, Ana Vega, Joseph Vijai, Qin Wang, Barbara Wappenschmidt, Clarice R. Weinberg, Jeffrey N. Weitzel, Camilla Wendt, Alicja Wolk, Siddhartha Yadav, Xiaohong R. Yang, Drakoulis Yannoukakos, Wei Zheng, Argyrios Ziogas, Kristin K. Zorn, Sue K. Park, Mads Thomassen, Kenneth Offit, Rita K. Schmutzler, Fergus J. Couch, Jacques Simard, Georgia Chenevix-Trench, Douglas F. Easton, Nadine Andrieu, Antonis C. Antoniou
Summary: Breast cancer risk for BRCA1/BRCA2 mutation carriers varies based on genetic factors. A case-only genome-wide association study identified novel loci associated with breast cancer risk for BRCA1/BRCA2 mutation carriers.
NATURE COMMUNICATIONS
(2021)
Review
Oncology
D. Huber, S. Seitz, K. Kast, G. Emons, O. Ortmann
Summary: This review analyzed the relationship between HRT use and cancer risk in BRCA mutation carriers. Most studies found no association between HRT and breast cancer risk, but different formulations and duration of use may have an impact on the risk modification.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Wojciech Marciniak, Tomas Matousek, Susan Domchek, Angelo Paradiso, Margherita Patruno, Arvids Irmejs, Irita Roderte, Roza Derkacz, Piotr Baszuk, Magdalena Kuswik, Cezary Cybulski, Tomasz Huzarski, Jacek Gronwald, Tadeusz Debniak, Michal Falco, Marcin R. Lener, Anna Jakubowska, Katherine Pullella, Joanne Kotsopoulos, Steven Narod, Jan Lubinski
Summary: The study revealed that elevated blood arsenic levels in women with BRCA1 mutations were significantly associated with an increased risk of developing breast cancer, suggesting a potential role of environmental arsenic in cancer development among this population.
Article
Obstetrics & Gynecology
Yukio Suzuki, Yongmei Huang, Alexander Melamed, Caryn M. St Clair, June Y. Hou, Fady Khoury-Collado, Allison Gockley, Melissa Accordino, Dawn L. Hershman, Jason D. Wright
Summary: This study aimed to examine the use of estrogen therapy and patterns of follow-up evaluation in premenopausal women who underwent bilateral salpingo-oophorectomy for benign gynecologic diseases. The study found a substantial decline in estrogen therapy use over the past decade.
OBSTETRICS AND GYNECOLOGY
(2022)
Article
Oncology
Neda Stjepanovic, Jan Lubinski, Pal Moller, Susan Randall Armel, William D. Foulkes, Nadine Tung, Susan L. Neuhausen, Joanne Kotsopoulos, Ping Sun, Sophie Sun, Andrea Eisen, Steven A. Narod
Summary: The prospective study on breast cancer risk in BRCA1 and BRCA2 mutation carriers aged 60 and above indicates that the risk of developing breast cancer remains high in this population. Hormone replacement therapy, family history, and oophorectomy were not associated with breast cancer risk.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Martha Hickey, Katrina M. Moss, Efrosinia O. Krejany, C. David Wrede, Alison Brand, Judy Kirk, Heather L. Symecko, Susan M. Domchek, Trevor Tejada-Berges, Alison Trainer, Gita D. Mishra
Summary: Vasomotor symptoms increase within 3 months after RRSO, but do not worsen over the next 12 months. Hormone therapy can reduce but not completely resolve vasomotor symptoms, and may improve quality of life, but not to pre-oophorectomy levels.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Francesca Mateo, Zhengcheng He, Lin Mei, Gorka Ruiz de Garibay, Carmen Herranz, Nadia Garcia, Amanda Lorentzian, Alexandra Baiges, Eline Blommaert, Antonio Gomez, Oriol Mirallas, Anna Garrido-Utrilla, Luis Palomero, Roderic Espin, Ana Extremera, M. Teresa Soler-Monso, Anna Petit, Rong Li, Joan Brunet, Ke Chen, Susanna Tan, Connie J. Eaves, Curtis McCloskey, Razq Hakem, Rama Khokha, Philipp F. Lange, Conxi Lazaro, Christopher A. Maxwell, Miquel Angel Pujana
Summary: Breast cancer risk for carriers of BRCA1 pathological variants is influenced by genetic factors, with HMMR being a potential contributor. Overexpression of HMMR has been found to increase the risk of Brca1-mutant breast cancer by modulating the cancer cell phenotype and tumor microenvironment. This study provides insight into the biological basis of increased risk for BRCA1-associated breast cancer.
NATURE COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Ngozi P. Paul, Adriana E. Galvan, Kunie Yoshinaga-Sakurai, Barry P. Rosen, Masafumi Yoshinaga
Summary: Arsenicals, one of the oldest treatments for various human disorders, have been paradoxically used as therapeutic agents since ancient times despite their toxicity. After the discovery of antibiotics, most arsenic-based drugs were abandoned, but recent years have seen a renewed interest in their clinical use. The current applications of arsenicals include antimicrobial, antiviral, antiparasitic, and anticancer uses. With the rise of antibiotic resistance and emerging pathogens, revisiting arsenicals as an effective treatment option is suggested.
Article
Genetics & Heredity
Jeanna M. McCuaig, Tracy L. Stockley, Sarah E. Ferguson, Danielle Vicus, Sarah Brennenstuhl, Karen Ott, Raymond H. Kim, Kelly A. Metcalfe
Summary: This study evaluated the psychological outcomes following tumor and germline genetic testing in individuals with HGSOC. The results showed a significant decrease in genetic testing-related distress following receipt of germline results with genetic counseling. Most individuals were satisfied with this model of care.
JOURNAL OF GENETIC COUNSELING
(2023)
Article
Oncology
Kelly A. Metcalfe, Steven A. Narod, Andrea Eisen, Aletta Poll, Neda Zamani, David McCready, Tulin D. Cil, Frances C. Wright, Jordan Lerner-Ellis, Jeanna McCuaig, Tracy Graham, Ping Sun, Mohammad R. Akbari
Summary: The objective of this study was to evaluate the pathogenic variant yield for nine cancer predisposition genes by testing criteria. Results showed that of the 1006 women studied, 100 women (9.9%) were found to have a pathogenic variant in one of the nine genes tested. The highest prevalence of pathogenic variants was found in women with triple-negative breast cancer (23%).
Article
Microbiology
Yi-Fei Wu, Jian Chen, Wan-Ying Xie, Chao Peng, Shi-Tong Tang, Barry P. P. Rosen, Andreas Kappler, Jun Zhang, Fang-Jie Zhao
Summary: We isolated a photosynthetic purple bacteria, Rhodobacter strain CZR27, from an arsenic-contaminated paddy soil and demonstrated its capacity to oxidize As(III) to As(V) using malate as a carbon source photosynthetically. Our study revealed the presence of anaerobic photosynthesis-coupled As(III) oxidation in paddy soils, highlighting the importance of light-dependent, microbe-mediated arsenic redox changes in paddy arsenic biogeochemistry.
ENVIRONMENTAL MICROBIOLOGY
(2023)
Article
Engineering, Environmental
Jian Chen, Barry P. Rosen
Summary: In this study, the broad diversity of structural domains in ArsMs was revealed through comparative analysis. The differences in the ArsM structure lead to variations in methylation efficiency and substrate selectivity. The C-terminal domain was found to play a role in modulating the rate of catalysis. Additionally, the relationship between arsenite efflux systems and methylation was examined.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Chiara Giovenino, Slavica Trajkova, Lisa Pavinato, Simona Cardaropoli, Verdiana Pullano, Enza Ferrero, Elena Sukarova-Angelovska, Silvia Carestiato, Paola Salmin, Antonina Rinninella, Anthony Battaglia, Luca Bertoli, Antonio Fadda, Flavia Palermo, Diana Carli, Alessandro Mussa, Paola Dimartino, Alessandro Bruselles, Tawfiq Froukh, Giorgia Mandrile, Barbara Pasini, Silvia De Rubeis, Joseph D. Buxbaum, Tommaso Pippucci, Marco Tartaglia, Marzia Rossato, Massimo Delledonne, Giovanni Battista Ferrero, Alfredo Brusco
Summary: By studying the frequency of non-random X chromosome inactivation (XCI) in the mothers of male patients and affected females with neurodevelopmental disorders (NDD), we found skewed XCI in a subgroup of undiagnosed NDD cases. Re-evaluation of genetic variants and clinical data improved the diagnostic yield, leading to the identification of new X-linked disorders.
EUROPEAN JOURNAL OF HUMAN GENETICS
(2023)
Article
Genetics & Heredity
Maria Pia Leone, Silvia Morlino, Grazia Nardella, Riccardo Pracella, Daniela Giachino, Luca Celli, Demetrio Baldo, Licia Turolla, Maria Piccione, Emanuela Salzano, Martina Buse, Patrizia Lastella, Marcella Zollino, Rachele Cantone, Enrico Grosso, Andrea Zonta, Barbara Pasini, Carmelo Piscopo, Ilaria De Maggio, Manuela Priolo, Corrado Mammi, Thomas Foiadelli, Chiara Trabatti, Salvatore Savasta, Achille Iolascon, Alessandro Ferraris, Valentina Lodato, Niccolo Di Giosaffatte, Silvia Majore, Angelo Selicorni, Antonio Petracca, Carmela Fusco, Mauro Celli, Vito Guarnieri, Lucia Micale, Marco Castori
Summary: Deleterious variants in collagen genes are the most common cause of hereditary connective tissue disorders. Adaptations of the ACMG/AMP criteria have been developed and validated for classifying these variants, reducing uncertainties and improving the clinical utility of molecular testing in this field.
Article
Oncology
Shijie Zhou, Filipe Cirne, Justin Chow, Arman Zereshkian, Louise Bordeleau, Sukhbinder Dhesy-Thind, Peter M. Ellis, Som D. Mukherjee, Nazanin Aghel, Darryl P. Leong
Summary: This study investigated the intermediate-term clinical outcomes of patients who underwent permissive cardiotoxicity. The results showed that 92% of patients completed the trastuzumab treatment, while 6% experienced severe left ventricular dysfunction or clinical heart failure and prematurely discontinued therapy. At the final follow-up, 14% of patients still had mild cardiotoxicity. Although most patients recovered their left ventricular function after trastuzumab discontinuation or completion, persistent cardiotoxicity was observed in some patients.
Review
Genetics & Heredity
Dylan Pelletier, Barbara Rivera, Marc R. Fabian, William D. Foulkes
Summary: MicroRNAs (miRNAs) are crucial for gene expression regulation, and their biogenesis depends on specific genes such as DROSHA, DGCR8, DICER1, and AGO1/2. Germline pathogenic variants (GPVs) in these genes lead to different genetic syndromes with diverse clinical manifestations. DICER1 GPVs are associated with tumor predisposition, while recent studies have shed light on the clinical consequences of GPVs in DGCR8, AGO1, and AGO2. This review provides an up-to-date summary on how GPVs in miRNA biogenesis genes affect miRNA biology and contribute to clinical manifestations.
TRENDS IN GENETICS
(2023)
Article
Biochemistry & Molecular Biology
Dylan Pelletier, Anne-Laure Chong, Mona Wu, Leora Witkowski, Sophie Albert, Nelly Sabbaghian, Marc R. Fabian, William D. Foulkes
Summary: The endoribonuclease DICER1 is crucial in microRNA biogenesis, generating mature single-stranded miRNAs by cleaving pre-miRNA stem-loops. Pathogenic variants in DICER1 result in DICER1 tumor predisposition syndrome (DTPS), a childhood-onset tumor susceptibility disorder. Germline DICER1 missense variants in the Platform domain have been found in patients with tumors associated with DTPS, which impair miRNA biogenesis by preventing DICER1 from producing mature miRNAs and binding to pre-miRNA stem-loops.
Article
Engineering, Environmental
Shi-Tong Tang, Xin-Wei Song, Jian Chen, Jie Shen, Bin Ma, Barry P. Rosen, Jun Zhang, Fang-Jie Zhao
Summary: This study identified a previously unknown gene, arsO, which encodes an enzyme called ArsO that oxidizes Sb(III) to Sb(V) under aerobic conditions. The enzyme plays a significant role in the detoxification of Sb(III) in the environment. The arsO gene is widely distributed and abundant in various environments affected by human activities.
ENVIRONMENTAL SCIENCE & TECHNOLOGY
(2023)
Review
Oncology
Claire Freycon, Philip J. Lupo, Leora Witkowski, Crystal Budd, William D. Foulkes, Catherine Goudie
Summary: This systematic review found that some patients with FOXO1 fusion-positive ARMS have pathogenic/likely pathogenic variants in cancer predisposing genes, but the causal relationship between CPS and FP-ARMS could not be determined. Only one patient was diagnosed with a cancer predisposition syndrome known to be associated with rhabdomyosarcoma. Clinicians cannot solely rely on FOXO1 fusion status to distinguish patients with/without CPS.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Kelly A. Metcalfe, Tuya Pal, Steven A. Narod, Susan Armel, Salma Shickh, Kathleen Buckley, Scott T. Walters, Sarah Brennenstuhl, Anita Y. Kinney
Summary: This study aimed to evaluate the effect of a theory-based behavioral intervention delivered by genetic counselors on the uptake of risk-reducing salpingo-oophorectomy (RRSO) by women with BRCA1 or BRCA2 pathogenic variants (PVs) compared to usual care. Findings showed that the intervention significantly reduced decisional conflict and increased knowledge at one-year, and resulted in a higher proportion of RRSO at two years compared to usual care.
Article
Oncology
Gabriele Roccuzzo, Silvia Giordano, Thomas Granato, Francesco Cavallo, Luca Mastorino, Gianluca Avallone, Barbara Pasini, Pietro Quaglino, Simone Ribero
Summary: The study investigates familial melanoma, a form of skin cancer with a genetic predisposition. The researchers aim to identify specific genetic mutations associated with familial melanoma and correlate them with distinct dermoscopic patterns. Understanding this relationship could lead to improved screening and timely detection of new tumors in high-risk individuals.
Article
Surgery
Robert Wenger, Helene Retrouvey, Kelly Metcalfe, John L. Semple
Summary: This study assessed the outcomes of fat grafting before two-stage implant-based breast reconstruction in patients who had undergone mastectomy and radiation therapy. Results showed that there were no reconstructive failures and the short-term complication rate was 5%. Two patients developed capsular contracture grade IV and four patients required additional fat grafting for contour deformities.
PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN
(2023)